TrialSite argues safer peptide supply does not establish drug safety
The commentary separates questions of manufacturing and sourcing quality from the unresolved question of clinical evidence.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 9 18:53 ETSource: TrialSite News
The wire
- 01TrialSite News published a commentary making the case that improving the supply chain for peptides does not by itself demonstrate that the products are safe or effective.
- 02The distinction matters for clinics and compounders who point to purity testing and sourcing as a proxy for clinical reassurance.
- 03This is opinion commentary rather than new data or regulatory action, and the underlying evidence base for many gray-market peptides remains thin.
From the source
Read at trialsitenews.comPeptide Showdown: A Safer Supply Is Not Proof of a Safe Drug
